A detailed history of Soleus Capital Management, L.P. transactions in Immunic, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 7,293,007 shares of IMUX stock, worth $8.61 Million. This represents 0.82% of its overall portfolio holdings.

Number of Shares
7,293,007
Previous 7,293,007 -0.0%
Holding current value
$8.61 Million
Previous $9.63 Million 15.9%
% of portfolio
0.82%
Previous 0.79%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.14 - $1.53 $7.97 Million - $10.7 Million
6,993,007 Added 2331.0%
7,293,007 $9.63 Million
Q1 2023

May 15, 2023

BUY
$1.35 - $2.87 $405,000 - $861,000
300,000 New
300,000 $447,000
Q1 2022

May 16, 2022

BUY
$9.54 - $14.26 $620,100 - $926,900
65,000 Added 37.14%
240,000 $2.71 Million
Q4 2021

Feb 14, 2022

BUY
$7.34 - $10.25 $1.28 Million - $1.79 Million
175,000 New
175,000 $1.68 Million

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $36.1M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Soleus Capital Management, L.P. Portfolio

Follow Soleus Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.